Eli Lilly said on February 6 it plans to release data from its late stage drug trial on its experimental weight-loss drug retatrutide in 2025, a few months earlier than expected. The company had ...

The new experimental weight loss drug, Retatrutide, is showing promising results. According to a study in the Annals of ...

have demonstrated significant weight loss of 14% over 68 weeks, tirzepatide 18% over 72 weeks, and retatrutide even 22% within 48 weeks. “These are numbers we cannot achieve with nutritional ...

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943 ... contributing to weight loss and metabolic health improvements. This multi-receptor activation yields ...

New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with ... the investigational triple agonist retatrutide (Lilly) and the oral ...

Lilly’s retatrutide, a “triple agonist” shot, could match bariatric surgery’s 25% weight loss, potentially adding billions in revenue by 2026. Valuation supports the potential for LLY ...

which showed weight loss of around 19% at 46 weeks in a study reported earlier at the ADA, but had also not reached a plateau. Lilly is losing no time in advancing retatrutide into phase 3 testing ...